Real-World Outcomes of Ivacaftor Treatment in People with Cystic Fibrosis: A Systematic Review.

The cross-sectional analysis of the LTSS showed a trend toward lower prevalence of S. aureus in the ivacaftor-treated versus the modulator untreated comparator cohort in 2014 (63.9% vs. 69.9%; p < 0.0001 in the US cohort and 29.8% vs. 33.9%; p = 0.1706 in the UK cohort) and of MRSA (23.3% vs. 29.4%; p < 0.0001 in the US cohort and 2.7% vs. 3.7%; p = 0.42 in the UK cohort) [ 29 ].

also in 53,322 other papers